Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients
Epilepsy & Behavior · 2024-01 · 150 · 109561
DOI: 10.1016/j.yebeh.2023.109561 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsy & Behavior, 2024-01. Verfasst von Roberto H Caraballo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Juan P Garrahan Hospital, Buenos Aires, Argentina. Electronic address: rhcaraballo@arnet.com.ar. Hauptthemen laut MEDLINE: Anticonvulsants, Brain Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVE: Here we present a multicenter series of patients with developmental epileptic encephalopathies (DEE) who were treated with brivaracetam (BRV) as add-on therapy. METHODS: Medical records of 42 patients with DEE treated with add-on BRV seen at four pediatric neurology centers in Argentina between January 2021 and July 2023 were retrospectively analyzed. RESULTS: We included 42 patients (26 males, 16 females) with a mean age of 7 years (SD, ± 3.8; median, 9; range, 2-16). The children had different types of childhood-onset treatment-resistant DEEs and received BRV as add-on therapy for a mean period of 2 years (SD, ± 1.3 years; median, 1.5 years; range, 0.5-3 years). Thirty-three patients received levetiracetam (LEV) before the introduction of BRV. In nine patients, BRV was started without prior LEV because of behavioral disturbances. Three patients (9.5 %) became seizure free and 26/42 patients (62.1 %) had a greater than 50 % decrease in seizures after a mean follow-up of 21 months. Ten patients (23.8 %) had a 25-50 % seizure reduction, while seizure frequency remained unchanged in two (4.7 %) and increased in one patient (2.4 %). The interictal EEG abnormalities improved in all the responders. Adverse effects, consisting of drowsiness, irritability, and decreased appetite, were observed in seven patients (16.6 %), but did not lead to treatment discontinuation. CONCLUSION: Brivaracetam was found to be effective, safe, and well tolerated in children with DEE. In patients on LEV with behavioral disturbances, BRV may be tried. BRV may also be given without a previous trial with LEV in patients with behavioral problems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Juan P Garrahan Hospital, Buenos Aires, Argentina. Electronic address: rhcaraballo@arnet.com.ar.
- Department of Neurology, Juan P Garrahan Hospital, Buenos Aires, Argentina.
- Centro de Neurología Infantil CENI, Gualeguaychú, Argentina.
- Department of Neurology, Hospital de Niño Jesús, Tucumán, Argentina.
Zitieren
APA
Caraballo, R. H., Reyes, G., Chacón, S., & Fortini, P. S. (2024). Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients. Epilepsy & Behavior, 150, 109561. https://doi.org/10.1016/j.yebeh.2023.109561
Vancouver
Caraballo RH, Reyes G, Chacón S, Fortini PS. Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients. Epilepsy & Behavior. 2024;150:109561. doi:10.1016/j.yebeh.2023.109561
BibTeX
@article{Caraballo2024,
author = {Caraballo, Roberto H and Reyes, Gabriela and Chacón, Santiago and Fortini, Pablo Sebastián},
title = {Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients},
journal = {Epilepsy & Behavior},
year = {2024},
volume = {150},
pages = {109561},
doi = {10.1016/j.yebeh.2023.109561}
}
EUVIMED